Keytruda Adjuvant Kidney Cancer Data Cement The Future Of IO

“Practice Changing” KEYNOTE-564 Data Presented At ASCO Plenary

 
• By Alaric DeArment

The data illustrate the growing importance of adjuvant settings of solid tumors for PD-1/PD-L1 inhibitors, which could make up more than one-quarter of their sales in 2025.

Human kidney on scientific background. 3d illustration
Merck & Co. presents "practice changing" data on Keytruda in adjuvant renal cell carcinoma • Source: Shutterstock

More from ASCO

More from Conferences